JAN (NYSE:JAN) Price Target Raised to $33.00

JAN (NYSE:JAN) had its target price increased by Scotiabank from $31.00 to $33.00 in a report published on Thursday, Marketbeat Ratings reports. Scotiabank currently has a sector outperform rating on the stock.

JAN has been the topic of a number of other reports. Weiss Ratings started coverage on shares of JAN in a research report on Thursday, August 6th. They set a “hold (c-)” rating on the stock. Barclays lifted their target price on shares of JAN from $33.00 to $34.00 and gave the company an “overweight” rating in a research note on Monday, August 31st. Raymond James Financial assumed coverage on shares of JAN in a report on Tuesday, June 16th. They set a “strong-buy” rating and a $34.00 price target on the stock. Morgan Stanley upped their price target on shares of JAN from $28.00 to $31.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 18th. Finally, KeyCorp increased their price objective on JAN from $28.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.44.

JAN Trading Up 0.3%

JAN stock opened at $30.31 on Thursday. JAN has a 52-week low of $22.76 and a 52-week high of $32.83. The company’s 50 day moving average price is $30.53.

JAN (NYSE:JAN) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.18). The business had revenue of $216.46 million during the quarter, compared to analysts’ expectations of $203.32 million. JAN’s revenue for the quarter was up 45.4% compared to the same quarter last year. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. Equities research analysts anticipate that JAN will post 0.97 EPS for the current fiscal year.

JAN Announces Dividend

The business also recently declared a monthly dividend, which will be paid on Tuesday, December 29th. Shareholders of record on Friday, December 18th will be given a $0.0475 dividend. The ex-dividend date of this dividend is Friday, December 18th. This represents a c) dividend on an annualized basis and a dividend yield of 1.9%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Engineers Gate Manager LP acquired a new stake in JAN in the 2nd quarter worth approximately $15,274,000. Wellington Management Group LLP acquired a new stake in shares of JAN in the second quarter worth $8,739,000. WINTON GROUP Ltd acquired a new stake in shares of JAN in the second quarter worth $2,985,000. Readystate Asset Management LP bought a new stake in shares of JAN during the 2nd quarter worth $1,724,000. Finally, Greenland Capital Management LP bought a new stake in shares of JAN during the 2nd quarter worth $575,000. Institutional investors and hedge funds own 6.27% of the company’s stock.

Trending Headlines about JAN

Here are the key news stories impacting JAN this week:

• Positive Sentiment: Janus Living closed an upsized $1.25 billion unsecured revolving credit facility, increasing total commitments from $600 million. The larger facility provides additional financial flexibility to fund senior-housing investments and corporate needs, although the prior $100 million delayed-draw term loan was terminated. Janus Living Announces Closing of Upsized $1.25 Billion Revolving Credit Facility
• Positive Sentiment: Jefferies initiated coverage with a Buy rating and a $36 price target, implying meaningful upside from recent trading levels and signaling confidence in Janus Living’s senior-housing platform.
• Positive Sentiment: Scotiabank raised its price target to $33 from $31 and assigned a Sector Outperform rating, adding further support to the bullish analyst outlook.
• Neutral Sentiment: Compass Point initiated coverage with a Neutral rating but set a $37 price target. The target is constructive, but the Neutral rating suggests analysts remain cautious about valuation, execution, or the company’s operating outlook.
• Negative Sentiment: Janus Living’s latest quarterly results remain a concern: adjusted earnings of $0.05 per share missed the $0.23 consensus estimate, despite revenue of $216.5 million exceeding expectations and rising 45.4% year over year. Investors may continue watching whether the company can convert revenue growth into stronger profitability while managing its expanded borrowing capacity.

About JAN

JanOne Inc is a technology and life sciences company focused on addressing the global opioid crisis. The company’s activities include developing and supporting pharmaceutical and other solutions intended to help reduce opioid-related deaths and dependency.

JanOne has also pursued blockchain and financial technology initiatives through its Alt 5 Sigma operations. These activities have included blockchain-based payment, digital asset and financial services solutions designed to help businesses manage transactions and related digital assets.

The company serves markets through its healthcare, technology and financial services initiatives, with an emphasis on solutions that can be applied internationally.